Education
About Us
Working with TipRanks
Follow Us
Teva Pharmaceutical (DE:TEV)
FRANKFURT:TEV
Earnings Data
Report Date
Feb 11, 2026Before Open (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
0.58Last Year’s EPS
0.61Same Quarter Last Year
Strong Buy
Based on 6 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
Teva demonstrated strong growth in its innovative portfolio and significant debt reduction, reinforcing confidence in long-term targets. However, challenges remain in the TAPI segment, European generics, and declining free cash flow, which offset some of the positive developments.Company Guidance
11th Consecutive Quarter of Growth
Teva reported its 11th consecutive quarter of growth with a 3% increase in revenue to $4.5 billion, an adjusted EBITDA up 6%, and a non-GAAP EPS increase of 14% compared to Q3 2024.
Innovative Portfolio Growth
Innovative products grew to over $800 million for the quarter, showing a 33% year-on-year growth. AUSTEDO grew by 38% to $618 million, UZEDY increased by 24% to $43 million, and AJOVY was up 19% to $168 million.
Reduction in Net Debt
Teva’s net debt to EBITDA is now below 3x for the first time since 2016, demonstrating financial discipline and effective debt reduction strategies.
Successful IRA Negotiations for AUSTEDO
The outcome of the IRA negotiations for AUSTEDO was in line with expectations, reinforcing confidence in achieving the revenue target of $2.5 billion in 2027 and over $3 billion at peak.
Generics and Biosimilars Performance
Global generics revenues increased by 2%, with the U.S. market growing 7% in Q3 due to several launches and strong biosimilar performances.
DE:TEV Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DE:TEV Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 05, 2025 | €17.45 | €21.60 | +23.78% |
Jul 30, 2025 | €14.20 | €14.70 | +3.52% |
May 07, 2025 | €14.35 | €14.60 | +1.74% |
Jan 29, 2025 | €20.80 | €18.00 | -13.46% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Teva Pharmaceutical (DE:TEV) report earnings?
Teva Pharmaceutical (DE:TEV) is schdueled to report earning on Feb 11, 2026, Before Open (Confirmed).
What is Teva Pharmaceutical (DE:TEV) earnings time?
Teva Pharmaceutical (DE:TEV) earnings time is at Feb 11, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Teva Pharmaceutical stock?
The P/E ratio of Teva Pharmaceutical is N/A.
What is DE:TEV EPS forecast?
DE:TEV EPS forecast for the fiscal quarter 2025 (Q4) is 0.58.
